The MPN Stem Cell Transplantation Timing Taskforce (MS3T)
Primary objective: Apply current evidence-based findings to more clearly define and communicate the optimal window of opportunity for stem cell transplant in MPNs on the basis of safety and efficacy.
To implement that objective the MS3T has two goals:
Goal 1: Better inform MPN patients on the process, risks, benefits, and optimal timing of stem cell transplant employing clear and graphic elements where possible.
Goal 2: Better inform non-MPN focused hematologists on contemporary thinking in identification of MPN SCT candidates; provide staged progression guidelines leading to optimal SCT timing; and share the best methods for having the transplant discussion with MPN patients.
Endpoint: Increase successful SCT outcomes by decreasing the incidence of delayed transplant in MPNs.
The MPN Research Foundation launch announcement to media is here.
Dr. Claire Harrison
Professor and Clinical Director, Guy’s and St. Thomas’ Hospital London
Dr. Ruben Mesa
Director, Mays Cancer Center of UT Health San Antonio MD Anderson Cancer Center
Dr. Richard T. Silver
Professor of Medicine, Weill-Cornell
Richard T Silver MD Myeloproliferative Neoplasms Center
Dr. Srdan Verstovsek
Department of Leukemia, UT MD Anderson Cancer Center, Houston
Dr. Koen Van Besien
Director, SCT program, Weill-Cornell
Dr. Nicolaus Kroeger
Medical Director, SCT, University Hospital, Hamburg
Dr. Jeanne Palmer
Medical Director, BMT, Mayo Clinic, Phoenix
Dr. Uday Popat
Professor Dept of SCT, MD Anderson
Dr. Attilio Orazi
Professor of Pathology, Director of Hematopathology, Weill-Cornell
Dr. Wael Saber
Scientific Director, CIBMTR, Associate Professor
Medical College of Wisconsin
MPN SCT Patients
MPN Patient Advocates
MPN Advocacy and Education, CEO
President and Founder, Genny’s Hope Foundation
Barbara Van Husen
CEO, MPN Research Foundation
Director, MPN Research Foundation
Editor & Publisher, MPN Quarterly Journal/MPNforum
The MPN Research Foundation